Search
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigational[L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … [A243356, A243361] Cilgavimab (formerly AZD1061) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigational[L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … [A243356, A243361] Tixagevimab (formerly AZD8895) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawn[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension. … Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalIt was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard
Mixtures: ZEPOSIA 7-Day Starter Pack, ZEPOSIA 7-Day Starter PackCarglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalFood and Drug Administration (FDA) on 18 March 2010. … Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase.
Agalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … Agalsidase alfa is a recombinant human α-galactosidase A similar to [agalsidase beta].
Synonyms: alpha-D-galactosidase, alpha-D-galactopyranosidaseDefibrotide
go.drugbank.com/drugs/DB04932ApprovedInvestigationalIt is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio. … Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA.
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist.
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Products: ONBREZ BREEZHALER 150UG HATick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigational[A237520] TICOVAC (also known as TicoVac or FSME-IMMUN) was the first approved vaccine against TBE in Europe, first approved in 1976. … [A237505] TBE often manifests in a biphasic manner, with patients experiencing a flu-like illness followed by a variable asymptomatic period and then a second phase characterized by various neurological